FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322768051> ?p ?o ?g. }

• W4322768051 endingPage "55" @default.
• W4322768051 startingPage "47" @default.
• W4322768051 abstract "Recurrent episodes of bronchial obstruction in preschool children are one of the important risk factors for the development of bronchial asthma.Purpose. The study aimed at investigating the clinical and immunological characteristics of children with acute bronchitis and to determine the clinical effectiveness of course anti-inflammatory therapy.Material and methods. The study was a single-center prospective cohort, including 1–5-year-old patients with acute bronchitis (main group, n = 109): a group with acute simple bronchitis (n = 34) and acute obstructive bronchitis (n = 75). Reference group: children of health group 2 (n = 29). Clinical and anamnestic and laboratory methods were used. Patients with a positive API (Asthma Predictive Index) were administered montelukast at a dose of 4 mg orally once a day for 3 months (control points at 1 and 3 months), reference patients received symptomatic therapy for respiratory infection. The end point of the study is the absence of bronchial obstruction. The effectiveness of the use of Montelukast was evaluated by calculating the clinical index, efficiency coefficient. Results. A statistically significant predominance of intoxication symptoms was found in patients with acute simple bronchitis (p = 0.02), signs of respiratory failure (p < 0.001), and peripheral eosinophilia — in children with acute obstructive bronchitis (p = 0.02). In etiology, rhinovirus significantly prevailed in patients with bronchial obstruction, and RS virus prevailed in patients with acute simple bronchitis (p = 0.02). The cytokine profile of patients with acute obstructive bronchitis is characterized by a decrease in the levels of macrophage inflammatory proteins (p = 0.01) and IL-8 (p = 0.048). A prolonged course of montelukast in children with a positive API significantly reduces the severity of subsequent acute respiratory infections, reduces the frequency of bronchial obstruction and the risk of bronchial asthma (p < 0.001).Conclusion. Evaluation of the results of montelukast therapy demonstrated clinical efficacy in patients with a positive API index." @default.
• W4322768051 created "2023-03-03" @default.
• W4322768051 creator A5002353093 @default.
• W4322768051 creator A5016610223 @default.
• W4322768051 creator A5031239772 @default.
• W4322768051 creator A5080689651 @default.
• W4322768051 date "2023-03-01" @default.
• W4322768051 modified "2023-09-27" @default.
• W4322768051 title "Clinical efficacy of antileukotriene therapy in children with acute bronchitis" @default.
• W4322768051 cites W2125178177 @default.
• W4322768051 cites W2291121870 @default.
• W4322768051 cites W2335562578 @default.
• W4322768051 cites W2568678743 @default.
• W4322768051 cites W2592471288 @default.
• W4322768051 cites W2620535556 @default.
• W4322768051 cites W2775307951 @default.
• W4322768051 cites W2792710439 @default.
• W4322768051 cites W2795880046 @default.
• W4322768051 cites W2900303093 @default.
• W4322768051 cites W2902952264 @default.
• W4322768051 cites W2939247829 @default.
• W4322768051 cites W2973583385 @default.
• W4322768051 cites W2980654983 @default.
• W4322768051 cites W2995175753 @default.
• W4322768051 cites W3004934177 @default.
• W4322768051 cites W3026830498 @default.
• W4322768051 cites W3125578388 @default.
• W4322768051 cites W3138410834 @default.
• W4322768051 cites W3200094539 @default.
• W4322768051 doi "https://doi.org/10.21508/1027-4065-2023-68-1-47-55" @default.
• W4322768051 hasPublicationYear "2023" @default.
• W4322768051 type Work @default.
• W4322768051 citedByCount "0" @default.
• W4322768051 crossrefType "journal-article" @default.
• W4322768051 hasAuthorship W4322768051A5002353093 @default.
• W4322768051 hasAuthorship W4322768051A5016610223 @default.
• W4322768051 hasAuthorship W4322768051A5031239772 @default.
• W4322768051 hasAuthorship W4322768051A5080689651 @default.
• W4322768051 hasBestOaLocation W43227680511 @default.
• W4322768051 hasConcept C126322002 @default.
• W4322768051 hasConcept C188816634 @default.
• W4322768051 hasConcept C2776042228 @default.
• W4322768051 hasConcept C2776322731 @default.
• W4322768051 hasConcept C2779993553 @default.
• W4322768051 hasConcept C71924100 @default.
• W4322768051 hasConcept C90924648 @default.
• W4322768051 hasConceptScore W4322768051C126322002 @default.
• W4322768051 hasConceptScore W4322768051C188816634 @default.
• W4322768051 hasConceptScore W4322768051C2776042228 @default.
• W4322768051 hasConceptScore W4322768051C2776322731 @default.
• W4322768051 hasConceptScore W4322768051C2779993553 @default.
• W4322768051 hasConceptScore W4322768051C71924100 @default.
• W4322768051 hasConceptScore W4322768051C90924648 @default.
• W4322768051 hasIssue "1" @default.
• W4322768051 hasLocation W43227680511 @default.
• W4322768051 hasOpenAccess W4322768051 @default.
• W4322768051 hasPrimaryLocation W43227680511 @default.
• W4322768051 hasRelatedWork W2043240135 @default.
• W4322768051 hasRelatedWork W2060952785 @default.
• W4322768051 hasRelatedWork W2123763929 @default.
• W4322768051 hasRelatedWork W2155991787 @default.
• W4322768051 hasRelatedWork W2161727369 @default.
• W4322768051 hasRelatedWork W2253726892 @default.
• W4322768051 hasRelatedWork W2619141725 @default.
• W4322768051 hasRelatedWork W2894848803 @default.
• W4322768051 hasRelatedWork W3181073615 @default.
• W4322768051 hasRelatedWork W4322724676 @default.
• W4322768051 hasVolume "68" @default.
• W4322768051 isParatext "false" @default.
• W4322768051 isRetracted "false" @default.
• W4322768051 workType "article" @default.